Strategic Partnerships IACTA has a pattern of forming licensing and strategic collaborations with biotech and ophthalmology companies (Pharmaleads, TALLC, Ora). Leverage these relationships to position complementary products or services that integrate with their ophthalmic portfolio and expand joint offerings.

Early Stage Funding The company has secured early-stage funding and government support (DoD funding, $1M; partnerships) indicating openness to grant-funded projects and preclinical collaborations. Sales opportunities exist in funded research programs, contract development, and translational studies.

Advisory Expansion Recent expansion of the Scientific Advisory Board signals ongoing clinical and technical advancement. Engage in high-level discussions about advisory services, consulting, or technology validation partnerships to support new ophthalmic drug development and safety profiling.

Ophthalmic Focus IACTA targets innovative eye care technologies and unmet ophthalmic needs. Opportunities exist to offer specialized CRO/CMC/clinical trial services, regulatory strategy, or digital health tools designed for ophthalmology outcomes and patient care improvement.

Global Collaboration With international partnerships (Montreal, Puerto Rico) and a global licensing approach, there is potential to propose cross-border clinical studies, regulatory milestones, and market-entry support for ophthalmic therapies in multiple regions.